Klimczak Katarzyna, Łykowska-Szuber Liliana, Krela-Kaźmierczak Iwona, Eder Piotr, Szymczak Aleksandra, Stawczyk-Eder Kamila, Linke Krzysztof
Katedra i Klinika Gastroenterologii, Żywienia Człowieka i Chorób Wewnętrznych Uniwersytetu Medycznego im. K. Marcinkowskiego w Poznaniu, Szpital Kliniczny im H. Święcickiego, Poznań, tel. 668408511 e-mail:
Katedra i Klinika Gastroenterologii, Żywienia Człowieka i Chorób Wewnętrznych Uniwersytetu Medycznego im. K. Marcinkowskiego w Poznaniu, Szpital Kliniczny im H. Święcickiego, Poznań
Wiad Lek. 2016;69(2 Pt 2):262-6.
M ethotrexate (MTX) as an immunomodulatory drug has numerous applications in autoimmune diseases. Autoimmune patomechanism is one of the factors responsible for development of inflammatory bowel diseases (IBD). MTX is an alternative therapy in the treatment of IBD. Over the past several years clinical trials has confirmed the efficacy of MTX in the treatment of Crohn's disease (CD). Data concerning use of MTX in ulcerative colitis (UC) are not as numerous as in the CD. Currently, MTX is recommended for the induction treatment and maintenance therapy in CD patients, especially in steroid-dependent patients, disease refractory to corticosteroids, no improvement after treatment with azathioprine and 6-mercaptopurine, or in case of intolerance to these drugs. Preferred route of administration in the treatment of CD is parenteral supply. Contraception is indicated during MTX treatment since it's teratogenic.
甲氨蝶呤（MTX）作为一种免疫调节药物在自身免疫性疾病中有众多应用。自身免疫发病机制是炎症性肠病（IBD）发生的因素之一。MTX是IBD治疗的一种替代疗法。在过去几年中，临床试验已证实MTX在治疗克罗恩病（CD）方面的疗效。关于MTX在溃疡性结肠炎（UC）中使用的数据不如在CD中那么多。目前，MTX被推荐用于CD患者的诱导治疗和维持治疗，特别是在依赖类固醇的患者、对皮质类固醇难治的疾病、用硫唑嘌呤和6-巯基嘌呤治疗后无改善或对这些药物不耐受的情况下。CD治疗的首选给药途径是胃肠外给药。MTX治疗期间需采取避孕措施，因为它具有致畸性。
